Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.51 |
| ▸ | PGR | P06401 | 5/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011613 | 0.87 | NR3C1 (0.62) | NR3C1PGRCYP11B2 | |
| SCHEMBL15505492 | 0.81 | NR3C1 (0.65) | NR3C1PGRCYP11B2CYP11B1 | |
| SCHEMBL30375949 | 0.81 | NR3C1 (0.60) | NR3C1PGRCYP11B2CYP11B1 | |
| SCHEMBL25800348 | 0.81 | NR3C1 (0.60) | NR3C1PGRCYP11B2CYP11B1 | |
| SCHEMBL30947650 | 0.81 | CYP11B2 (0.52) | NR3C1PGRCYP11B2CYP11B1 | |
| SCHEMBL14852598 | 0.77 | CYP11B2 (0.52) | NR3C1CYP11B2IRAK4CYP11B1 | |
| SCHEMBL29623687 | 0.77 | CYP11B2 (0.52) | NR3C1PGRCYP11B2CYP11B1 | |
| SCHEMBL20603941 | 0.77 | CYP11B2 (0.52) | NR3C1PGRCYP11B2CYP11B1 | |
| SCHEMBL1542061 | 0.77 | NR3C1 (0.55) | NR3C1PGRCYP11B2 | |
| SCHEMBL1542086 | 0.77 | NR3C1 (0.57) | NR3C1PGRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753611-B1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2753611-B1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9193744-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193744-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193744-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2892527-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | AbbVie Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20140162985-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162985-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162985-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014039757-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014039757-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2013034048-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034048-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | EIF5B, EIF2AK2, HCCS | NR3C1 2303/4885PGR 2762/4885CYP11B2 371/4885 |
| US-20140162985-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | NR3C1 6/4885PGR 26/4885CYP11B2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.